US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

iShares Expanded Tech Sector ETF

94.39

+2.712.96%

Post-market: 94.390.00000.00%18:48 EDT

Volume:413.20K

Turnover:38.78M

Market Cap:5.43B

PE:5.20

High:94.49

Open:92.96

Low:92.87

Close:91.68

Loading ...

Overview Company News Filings

RBC Downgrades IGM Biosciences to Sector Perform From Outperform, Slashes Price Target to $1.50 From $20, Keeps Speculative Risk Qualifier

MT Newswires Live

IGM Biosciences Shares Down 69% Following Treatment Development Halt, Workforce Reduction

IGM Biosciences downgraded to Neutral from Buy at Guggenheim

IGM Biosciences Cut to Market Perform From Outperform by BMO Capital

IGM Biosciences downgraded to Hold from Buy at Stifel

IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley

IGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan Stanley

IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences to Slash Workforce by 73%, Halt Two Drug Programs, Evaluate Alternatives

MT Newswires Live

IGM Biosciences to Halt Development of Imvotamab, Cut 73% of Staff

IGM Biosciences halting further development of imvotamab and IGM-2644

BRIEF-IGM Biosciences Reduces Its Workforce By 73%

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes

MT Newswires Live

Exchange-Traded Funds, US Equities Firmer After Midday Trading

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IGM/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IGM"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGM\",,,,,undefined,":{"symbol":"IGM","market":"US","secType":"STK","nameCN":"iShares Expanded Tech Sector ETF","latestPrice":94.39,"timestamp":1741982400000,"preClose":91.68,"halted":0,"volume":413201,"hourTrading":{"tag":"盘后","latestPrice":94.39,"preClose":94.39,"latestTime":"18:48 EDT","volume":12349,"amount":1158486.606,"timestamp":1741992494693},"delay":0,"changeRate":0.029559,"change":2.71,"floatShares":57500000,"shares":57500000,"eps":18.152277,"lyrEps":-14.08313,"pbRate":1.74,"amount":38780570.78601,"amplitude":0.017646,"volumeRatio":0.8344480820360235,"dividePrice":0.2701,"prevYearClose":102.09,"fiveDayClose":96.47,"twentyDayClose":107.8,"impliedVol":0.4498,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGM\",,,,,undefined,":{"symbol":"IGM","floatShares":57500000,"roa":"0.21%","roe":"30.06%","lyrEps":-14.08313,"volumeRatio":0.8344480820360235,"shares":57500000,"dividePrice":0.2701,"high":94.49,"amplitude":0.017646,"preClose":91.68,"low":92.8722,"week52Low":79.675,"pbRate":"1.74","psRate":"244.79","week52High":108.729,"institutionHeld":0,"latestPrice":94.39,"eps":18.152277,"divideRate":0.002862,"volume":413201,"delay":0,"ttmEps":18.152277,"open":92.96,"prevYearClose":102.09,"prevWeekClose":96.47,"prevMonthClose":100.09,"prevQuarterClose":102.09,"fiveDayClose":96.47,"twentyDayClose":107.8,"sixtyDayClose":105.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IGM\",params:#limit:5,,,undefined,":[{"date":"2024-12-17","symbol":"IGM","amount":0.0496,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Expanded Tech Sector ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-09-25","symbol":"IGM","amount":0.09458,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"iShares Expanded Tech Sector ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-11","symbol":"IGM","amount":0.04047,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Expanded Tech Sector ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2024-03-21","symbol":"IGM","amount":0.03803,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-22","defaultRemindTime":1711027800000,"name":"iShares Expanded Tech Sector ETF","recordDate":"2024-03-27","payableDate":"2024-03-22","currency":"USD","dateTimestamp":1710993600000,"payDate":"2024-03-27"},{"market":"US","date":"2024-03-07","symbol":"IGM","defaultRemindTime":1709821800000,"type":"split","dateTimestamp":1709787600000,"forFactor":1,"toFactor":6,"ratio":0.16666666666666666}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IGM\",market:\"US\",,,undefined,":[{"executeDate":"2015-03-25","recordDate":"2015-03-27","paymentDate":"2015-03-31","value":0.189025,"currency":"USD"},{"executeDate":"2015-06-24","recordDate":"2015-06-26","paymentDate":"2015-06-30","value":0.2323559,"currency":"USD"},{"executeDate":"2015-09-25","recordDate":"2015-09-29","paymentDate":"2015-10-01","value":0.188956,"currency":"USD"},{"executeDate":"2015-12-24","recordDate":"2015-12-29","paymentDate":"2015-12-31","value":0.2605669,"currency":"USD"},{"executeDate":"2016-03-23","recordDate":"2016-03-28","paymentDate":"2016-03-30","value":0.312847,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IGM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IGM\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2502359859","title":"RBC Downgrades IGM Biosciences to Sector Perform From Outperform, Slashes Price Target to $1.50 From $20, Keeps Speculative Risk Qualifier","url":"https://stock-news.laohu8.com/highlight/detail?id=2502359859","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502359859?lang=en_us&edition=fundamental","pubTime":"2025-01-10 19:20","pubTimestamp":1736508053,"startTime":"0","endTime":"0","summary":"IGM Biosciences (IGMS) has an average rating of hold and mean price target of $15.06, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IGMS","IGM"],"gpt_icon":0},{"id":"2502859368","title":"IGM Biosciences Shares Down 69% Following Treatment Development Halt, Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2502859368","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502859368?lang=en_us&edition=fundamental","pubTime":"2025-01-10 19:20","pubTimestamp":1736508000,"startTime":"0","endTime":"0","summary":"IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments.Shares were trading around $1.94. The stock is up 1.5% on the year.The biotechnology company said its decision to halt development would pertain to imvotamab and IGM-2644. It also cut its staff by 73% and is exploring internal options and strategic alternatives to maximize shareholder value while it looks to conserve cash.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGMS","BK4505","BK4139","IGM"],"gpt_icon":0},{"id":"2502856482","title":"IGM Biosciences downgraded to Neutral from Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2502856482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502856482?lang=en_us&edition=fundamental","pubTime":"2025-01-10 19:11","pubTimestamp":1736507496,"startTime":"0","endTime":"0","summary":"Guggenheim downgraded IGM Biosciences (IGMS) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-neutral-from-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-neutral-from-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGM","IGMS"],"gpt_icon":0},{"id":"2502307568","title":"IGM Biosciences Cut to Market Perform From Outperform by BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502307568","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502307568?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:08","pubTimestamp":1736503680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IGMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 05:08 ET (10:08 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGMS","IGM","BMO"],"gpt_icon":0},{"id":"2502003418","title":"IGM Biosciences downgraded to Hold from Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2502003418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502003418?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:55","pubTimestamp":1736474119,"startTime":"0","endTime":"0","summary":"Stifel downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company’s “surprising deci...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-hold-from-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-hold-from-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGM","SF","IGMS"],"gpt_icon":0},{"id":"2502798003","title":"IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2502798003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502798003?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:50","pubTimestamp":1736473837,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences (IGMS) to Underweight from Equal Weight with a price target of $2, down from $12. The...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-underweight-from-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-underweight-from-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGMS","IGM"],"gpt_icon":0},{"id":"2502086220","title":"IGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2502086220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502086220?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:35","pubTimestamp":1736472914,"startTime":"0","endTime":"0","summary":"IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/igm-biosciences-igms-was-downgraded-to-a-sell-rating-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/igm-biosciences-igms-was-downgraded-to-a-sell-rating-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGM","IGMS"],"gpt_icon":0},{"id":"2502279280","title":"IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502279280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502279280?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:30","pubTimestamp":1736458218,"startTime":"0","endTime":"0","summary":"BMO Capital downgraded IGM Biosciences (IGMS) to Market Perform from Outperform with a price target of $2, down from $21, following the company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-market-perform-from-outperform-at-bmo-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/igm-biosciences-downgraded-to-market-perform-from-outperform-at-bmo-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGM","BMO","IGMS"],"gpt_icon":0},{"id":"2502910026","title":"IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out","url":"https://stock-news.laohu8.com/highlight/detail?id=2502910026","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502910026?lang=en_us&edition=fundamental","pubTime":"2025-01-10 03:28","pubTimestamp":1736450880,"startTime":"0","endTime":"0","summary":"Stock is already down 54% in the last three months after the company switched to autoimmunity from oncology late last year. IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline.The company  had 198 full-time employees as of the end of September, according to its most recent 10-Q regulatory filing, meaning that about 144 workers will be affected.Interim data from early stage trials of the company's imvotamab as a treatment for rheumatoid arthritis and systemic lupus erythematosus \"show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success,\" Mary Beth Harler, chief executive of IGM Biosciences, said in a statement.The Mountain View, Calif.-based company is also scrapping its IGM-2644 treatment for autoimmune diseases as part of the move.For more, read: IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU2242646821.SGD","IGM","LU0868494617.USD","LU0306807586.USD","LU1093756325.SGD","BK4139","IE00B2B36J28.USD","LU0321505868.SGD","LU1670711040.USD","LU1093756168.USD","BK4505","BK4581","LU0225284248.USD","IGMS","LU1585245621.USD","LU0882574055.USD","LU1868836914.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU1868836757.USD","LU2125154778.USD","LU1670710661.SGD","LU2133065610.SGD","BMY","LU2360032135.SGD","LU0096364046.USD","LU0321505439.SGD","LU0985481810.HKD","BK4534","LU1571399168.USD","LU1074936037.SGD","LU1718418525.SGD","LU1989771016.USD","LU1868837300.USD","LU1032466523.USD","LU1868836591.USD","LU2242652126.USD","IE0009355771.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","BK4007","IE00BFTCPJ56.SGD","LU0225771236.USD","LU1868837136.USD","LU0061475181.USD","BK4588","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2502023280","title":"IGM Biosciences to Slash Workforce by 73%, Halt Two Drug Programs, Evaluate Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2502023280","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502023280?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:39","pubTimestamp":1736447940,"startTime":"0","endTime":"0","summary":"IGM Biosciences (IGMS) plans to slash its workforce by 73% to preserve cash and assess strategic alternatives to maximize value for shareholders.Developments of the imvotamab and IGM-2644 autoimmunity","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","IGM","IGMS"],"gpt_icon":0},{"id":"2502202808","title":"IGM Biosciences to Halt Development of Imvotamab, Cut 73% of Staff","url":"https://stock-news.laohu8.com/highlight/detail?id=2502202808","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502202808?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:23","pubTimestamp":1736446980,"startTime":"0","endTime":"0","summary":"IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%.The biotechnology company said interim data from Phase 1b studies showed insufficient B cell depletion for imvotamab in treating rheumatoid arthritis and lupus.IGM-2644 is also being terminated following strategic considerations.The company is now exploring internal options and strategic alternatives to maximize shareholder value, while implementing a 73% workforce reduction to conserve cash.As of Dec. 31, IGM had $183.8 million in cash and investments.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGM","IGMS","BK4505","BK4139"],"gpt_icon":0},{"id":"2502028226","title":"IGM Biosciences halting further development of imvotamab and IGM-2644","url":"https://stock-news.laohu8.com/highlight/detail?id=2502028226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502028226?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:10","pubTimestamp":1736446217,"startTime":"0","endTime":"0","summary":"IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell en...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/igm-biosciences-halting-further-development-of-imvotamab-and-igm-2644?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/igm-biosciences-halting-further-development-of-imvotamab-and-igm-2644?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IGMS","BK4139","IGM","BK4505"],"gpt_icon":0},{"id":"2502590028","title":"BRIEF-IGM Biosciences Reduces Its Workforce By 73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502590028","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502590028?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:04","pubTimestamp":1736445845,"startTime":"0","endTime":"0","summary":"Jan 9  - IGM Biosciences Inc   :   * IGM BIOSCIENCES PROVIDES STRATEGIC UPDATE ON AUTOIMMUNITY PIPELINE PROGRAMS   * IGM BIOSCIENCES INC -COMPANY REDUCING ITS WORKFORCE BY 73%   * IGM BIOSCIENCES INC -COMPANY HALTING FURTHER DEVELOPMENT OF IMVOTAMAB  AND IGM-2644    * IGM BIOSCIENCES INC - CURRENTLY EVALUATING INTERNAL OPTIONS AS WELL AS POTENTIAL STRATEGIC ALTERNATIVESSource text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IGM","IGMS","BK4139"],"gpt_icon":0},{"id":"2502583028","title":"IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2502583028","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502583028?lang=en_us&edition=fundamental","pubTime":"2025-01-10 02:00","pubTimestamp":1736445600,"startTime":"0","endTime":"0","summary":"– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) –  – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of Decemb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007285/0/en/IGM-Biosciences-Provides-Strategic-Update-on-Autoimmunity-Pipeline-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","IGM","IGMS"],"gpt_icon":0},{"id":"2501243437","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2501243437","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501243437?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:12","pubTimestamp":1736341956,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively traded Invesco QQQ Trust (QQQ) lost 0.4% in Wednesday's premarket activity, ahead of the Federal Open ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US30Y.BOND","GLD","SPY.AU",".SPX","US5Y.BOND","IYJ","BSX","ANSS","IYW","EQR","XSD","XLK","BSX.AU","XTIA","XLP","IYH","US6M.BOND","XLF","IVV","UNG","IYE","IGV","FAZ",".IXIC","RTH","XLI","XLV","SNPS","US3Y.BOND","XRT","IBB","SLV","EEM","VHT.AU",".DJI","US7Y.BOND","HELE","SPY","SOXX","US10Y.BOND","US12M.BOND","USO","IGM","EXI","RTH.AU","US2Y.BOND","FOMC","FDN","PMR"],"gpt_icon":1},{"id":"2501930263","title":"Exchange-Traded Funds, US Equities Firmer After Midday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2501930263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501930263?lang=en_us&edition=fundamental","pubTime":"2025-01-07 02:13","pubTimestamp":1736187218,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded fund IWM and IVV were higher. Actively traded Invesco QQQ Trust (QQQ) advanced 1.4%.US equity indexes rose, with chip stocks boosting the technology","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNG","VHT","VDC","XLE","XRT","BK4588","GLD","IGM","FDN","BK4581","SOXX","VIS","BK7050","RTH.AU","IBB","IYH","USO","SCO","XLI","FAZ","XLY","BK4504","BK4547","VHT.AU","XLF","FAS","QQQ","XLV","XLK","BK4593","IYJ","BK4534","SLV","XSD","RTH","IYW","UCO","IYK","BK4570","XLP","BK4585","BK4550","IYE","BK7094","BK4561"],"gpt_icon":1}],"pageSize":16,"totalPage":13,"pageCount":6,"totalSize":200}]}}